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Background: Hypoxia is an important feature of most solid tumors and has shown to 
serve as a mediator for aggressive tumor growth and malignant progression of cancer. A 
correlation between low oxygen tension in tumors and increased predisposition for 
metastatic dissemination through epithelial to mesenchymal transition (EMT) has been 
reported. Research has shown significant anti-malignant effects of hyperbaric oxygen 
(HBO) treatment on chemically-induced and murine breast tumors. Thus, to establish 
whether HBO has a general effect on breast cancer, the overall aim of the present study 
was to target the hypoxic tumor microenvironment by enhancing oxygenation in human 
and murine breast cancer models. We investigated the effect of HBO on growth and 
metastasis of human and murine breast cancer cells in vivo, in addition to establish 
expression of major EMT markers and thus the metastatic potential.                                                                              
Methods: A total of 24 balb/c and 12 nod/scid female mice were injected with 5 x 105 
breast cancer cells (human MDA-231 or murine 4T1 and 4T1-L) into the mammary fat 
pad at day 1. After tumor development the mice were divided into HBO treatment and 
control groups. Treatment consisted of 2.5 bar HBO exposure for 90 minutes, from day 7 
post injection and every third day for 22, 25 or 53 days (4T1, 4T1-L and MDA-231 
respectively) and non-treatment at normal atmospheric pressure. Mice with 4T1-L 
tumors were also used for biophotonic imaging to visualize cancer cells in vivo. Primary 
tumors were investigated for N- and E-cadherin expression by western blot and organs 
(lung and liver) were used for metastasis detection by histomorphometric quantification.        
Results and conclusion: Repeated HBO treatment significantly reduced tumor growth 
and metastasis to lungs in the human (MDA-231) and murine (4T1-L) breast cancer 
model without affecting the murine 4T1 model. In vivo imaging of balb/c mice with 4T1-L 
tumors confirmed reduced tumor size compared to control but detected no metastases 
to distant sites. HBO treatment influenced EMT through downregulation of N-cadherin 
expression in human (MDA-231) primary tumors. The reduced metastatic potential could 
in part be attributed to this downregulation. Thus, HBO might be a possible potential 






1.1   Cancer 
Cancer is not one, but a group of diseases defined by abnormal cell growth (neoplasia), 
that acquire the ability to spread to other parts of the body. Over 100 types of cancer 
have been classified and the tissue of origin gives the cancer its distinguishing 
characteristics. Neoplastic cells generally grow to form solid masses of tissue called 
tumors, but some grow in cell suspension (e.g. leukemia’s). Neoplastic cells can either 
be benign or malignant, and only the latter is synonymous with cancer (1). For the 
remaining part of the thesis malignant neoplasms are referred to as tumors. Tumor 
grading is a normal procedure during staging a cancer, and depends on how abnormal 
the tumor tissue morphology appears histologically. Tumors have a considerably 
increased rate of growth (proliferation) and show varying degrees of cell differentiation. 
Tumor cells that are poorly differentiated are called anaplastic cells. Normally, the 
grading system ranges from grade 1, where less than 25% of cells are anaplastic to 
grade 5, where over 75% of cells are anaplastic  (1, 2). Despite the specific tumor 
heterogeneity, tumors share some common traits that will be described below.  
 
1.1.1   Hallmarks of cancer 
In 2000, Hanahan and Weinberg (3)  described the “Hallmarks of cancer” to which they 
proposed six biological capabilities that define the development and progression of 
tumors. Since then, two emerging hallmarks and two enabling characteristics have been 
added to the list (4). Although the underlying cellular and molecular course of cancer is 





1. Sustaining proliferative signaling 
Cancer cells acquire mutations that short circuit growth factor pathways, rendering them 
independent on external growth factor signaling. Normal growth regulation is therefore 
avoided, leading to unregulated proliferation. 
2. Evasion of growth inhibitory signals 
Maintaining homeostasis is avoided by interference with inhibitory pathways and 
mutated cancer cells do not respond to growth inhibitory signals. For example, the 
normal tumor suppressor gene p53 responds to intracellular stress and arrest the cell 
division cycle. However, a mutated p53 does not produce functional growth inhibitory 
proteins, and cell division is not under control. 
3. Evasion of apoptosis 
Normal cells undergo apoptosis to limit growth of DNA damaged cells. However, cancer 
cells can acquire apoptotic resistance through different mutations, and secrete anti-
apoptotic signaling proteins. 
4. Unlimited replicative potential 
The activation of the enzyme telomerase by cancer cells maintains the length of 
telomeres, which allows the cell to replicate indefinitely. 
5. Angiogenesis 
Growing tumors are dependent on elevated blood supply to provide enough oxygen and 
nutrients to the increasing number of cells. They are therefore able to stimulate the 
formation of new blood vessels, called angiogenesis through activation of the 
“angiogenic switch” (5). An alteration between angiogenic inducers and inhibitors 






6. Invasion and metastasis 
Unlike normal cells, cancer cells do not maintain their location, but migrate and invade 
other tissues in the body by a process called metastasis. This process is responsible for 
most cancer-related deaths. 
7. Avoiding immune destruction 
An emerging hallmark is the strategy for cancer cells to evade attack and destruction by 
immune cells. Poorly immunogenic cells are able to replicate and escape 
“immunosurveillance”. Furthermore, cancer cells have shown to reduce the immune 
response by secreting immunosuppressive factors such as transforming growth factor-
beta (TGF-β) (6). 
8. Deregulating cellular energetics 
The second emerging hallmark represents a major reprogramming of cellular energy 
metabolism in order to support continuous growth and proliferation. In addition to 
switching to glycolysis for energy production, cancer cells can up-regulate specific 
transporters like GLUT1 thereby enhancing glucose utilization (7).   
 
1.1.2   Enabling characteristics 
1. Tumor-promoting inflammation 
Recently, researchers have discovered that the tumor-associated inflammatory 
response is in fact enhancing tumorigenesis and progression. Studies have shown that 
T and B lymphocytes have functional tumor-promoting effects through regulation of the 
innate immune system (8), and that inflammatory cells contribute to enhancing 





2. Genomic instability 
The ability of tumor cells to acquire the hallmarks of cancer largely depends on multiple 
genetic alterations over time. Certain mutated genotypes confer an advantage to sub 
clones in order to facilitate sustained growth in the local tissue. The rate of mutation in 
tumor cells has been shown to increase during the course of tumorigenesis through 
heightened sensitivity to mutagenic agents. (11).    
 
1.2 Breast Cancer 
Breast cancer remains the most frequent type of cancer among females worldwide, with 
1.67 million new patients diagnosed in 2012. It is the most leading cause of cancer 
mortality in females with more than 500 000 deaths annually (12). According to the 
Norwegian Cancer Registry, 31 651 new cancer cases were registered in the country in 
2014. Over 3300 of these cases were breast cancers, making it the second most 
prevalent type after prostate cancer (13). It is far more dominant in western countries 
than in Africa, South America or Asia (12), and several causative agents have been 
implicated with the pathogenesis of breast cancer. These include age, genetics, family 
history, diet, smoking, alcohol, obesity, physical inactivity and endocrine factors (14). 
However, as with most types of cancer, the exact mechanisms behind cancer 
development are still unknown. Males can also develop breast tumors, however it is 100 
times less common than among females. The risk of developing breast tumors in males 
is estimated to be 1 in 1,000, compared to an estimated 1 in 8 for women (12). 
 
1.2.1 Anatomic characterization  
The female breast consists of glandular tissue, milk-producing lobules and small ducts 




tissue surround the glands and ducts. Lymph vessels are also connected to the breast 









Figure 1: Anatomy of the female breast, frontal view. With permission (16). 
 
Breast cancer usually arises in the cells lining the milk ducts (80%), but also in cells 
lining the lobules (10%). They start out as either ductal or lobular carcinomas in situ with 
increased risk of developing invasive breast carcinoma. In fewer cases (10%), breast 
cancer leads to inflammation by from blocked lymph vessels (inflammatory breast 
cancer) or cancer arises from connective tissues between the ducts and lobules (17).  
 
1.2.3 Genetic characterization  
Breast tumors contain oncogenes and/or tumor-suppressor genes that could induce 
cancer and promote aggressive tumor growth. These may be inherited or arise from 




knock-out of both alleles to lose its function, whilst oncogenes are dominant and require 
only one mutated allele to produce mutated protein product (1).  
Specific inherited mutated genes have been identified as high penetrance susceptibility 
genes that confer an increased risk of developing breast cancer. About five to ten 
percent of breast cancer incidents develop from germ-line mutations in the BRCA1 and 
BRCA2 genes, located on chromosome 17 and chromosome 13, respectively. The risk 
for developing breast cancer for gene-positive patients is 57% for BRCA1 and 49% for 
BRCA2 (18). Normal functional versions of these genes produce tumor suppressor 
proteins that helps repair DNA damage. Mutated versions either produce dysfunctional 
proteins or do not express the protein at all (14). Consequently, to avoid developing 
breast cancer, many women with confirmed BRCA1 and BRCA2 mutations choose to 
undergo radical mastectomy and oophorectomy.  
 
1.2.4 Subtypes 
Research continues to demonstrate molecular and genetic differences in breast cancer, 
implying a demand to elucidate the unique characteristics of the primary tumor to better 
understand tumor-host interaction. Hence, breast cancer has been classified into 
subtypes that rely heavily upon the underlying molecular histopathological features of 
the primary tumor. More detailed molecular profiles of subtyping tumors have been 
proposed by researchers, however the most common types are outlined below. These 
subtypes differ vastly in behavior and respond differently to treatments. 
 
HER2 positive breast cancer 
Approximately 20-30% of breast tumors contain over-expression of the human 
epidermal growth factor receptor 2 (HER2) that results from the up-regulated HER2 
oncogene. The action of the over-expressed HER2 results in uncontrolled cell growth 




than HER2 negative breast cancers (1, 19). In addition, HER2 positive cancers seem to 
predict poorer prognosis and overall survival for patients. However, treatment with 
trastuzumab, a humanized monoclonal antibody targeting HER2 has shown to improve 
the prognosis of these aggressive cancers. Today, adjuvant trastuzumab therapy is 
therefore offered to cancer patients with “HER2” positive breast cancer in combination 
with chemotherapy (20, 21).  
Endocrine receptor-positive breast cancer 
Most breast cancers (80%) are “ER-positive”, meaning that the cancer cells grow in 
response to the hormone estrogen. Of these cases, approximately 65% also grow in 
response to progesterone, called “PR-positive”. ER-positive breast cancers respond well 
to hormone therapy that include estrogen receptor inhibitors (e.g. tamoxifen) and 
aromatase inhibitors for post-menopausal women (e.g letrozole) to lower estrogen levels 
(22). In addition, hormone ER-positive breast cancer is generally seen as treatable and 
manageable, especially if caught at an early stage. 
Triple positive breast cancer 
Breast cancers that are ER-positive, PR-positive and HER2 positive are referred to as 
triple positive breast cancers (TPBC). These cancer cells grow in response to the 
hormone estrogen, progesterone and contain the HER2 proto-oncogene, and thus, 
respond well to hormone therapy and HER2 inhibitors (23). 
Triple negative breast cancer 
Breast cancers which are endocrine receptor- and HER2-negative are referred to as 
triple negative breast cancer (TNBC). The TNBC cells do not express estrogen or 
progesterone receptors and do not contain HER2 over-expression. Consequently, due to 
the lack of effective targeted  therapies previously mentioned, TNBC is difficult to treat 
(24). In addition, TNBC is associated with increased metastatic potential, high 
recurrence rate and decreased five-year survival rate. The standard treatment involves 




of all breast cancers, in which younger women seem to have a higher risk of developing 
than older women (23, 25).  
 
1.3 Metastasis 
Metastasis is the spread of tumor cells from its primary site throughout the body and is a 
distinct characterization of malignant tumors. The process of metastasis is initiated when 
tumor cells lose their adhesive properties and detach from the primary tumor. They 
intravasate and migrate through the blood or lymphatic system. The circulating cancer 
cells finally adhere, proliferate and form micro-metastases at a distant site (1). This 
represents a major clinical problem in cancer treatment. In breast cancer, the primary 
tumor can often easily be removed surgically, however over 50% of tumors have 
metastasized at the time of diagnosis and often includes hundreds of metastases that 
are practically impossible to remove. Even 30% of cases initially diagnosed at an early 
stage will develop metastatic tumors months or years later (26). Metastatic spread of 
breast cancer is responsible for 90% of breast cancer-related deaths and thus 
represents the most important negative prognostic predictor. Perhaps the most lethal 
consequence of metastasis is the ability of tumor cells to compete with normal cells for 
nutrients and oxygen, which eventually impair normal organ function (1, 14).  
Breast cancer metastasis usually occurs in lymph nodes, bone, lungs, liver and brain 
(27, 28). In theory, blood flow to organs in close proximity to the primary tumor is the 
most likely sites of metastasis. However, studies have shown that it metastasizes to 
bone more likely than blood flow/anatomy would suggest (1). In addition, breast cancer 
subtypes display a marked difference in metastatic patterns. TNBC show increased 
visceral metastases, meaning metastases to internal organs such as liver, lungs and 
body cavities. Hormone receptor-positive tumors however, tend to show increased 
metastases to bone. HER2-positive tumors show an increased tendency to metastasize 




mechanisms behind these observations remain to be elucidated, a possible explanation 
is the so-called “seed and soil” theory. It suggests that tumor cells are “seeds” that need 
to be in a favoring microenvironment, being the “soil”. Furthermore, unique biochemical 
and physical characteristics of bone such as growth factors and acidic pH are properties 
that promotes tumor growth and could explain the increased observation of breast tumor 
cells in bone (30). Finally, an extensive review by Redig et al. (27) elucidating the 
complex molecular metastasis pattern of different breast cancer subtypes, suggested 
that future breast cancer treatment should focus more on targeting the specific 
processes that lead to metastasis. 
Since metastasis is so detrimental and the metastatic pattern differ vastly according to 
breast cancer subtypes, recognition and understanding of the metastatic process and its 
contributors is paramount for developing new cancer treatments. 
 
1.3.1 Epithelial to mesenchymal transition 
Epithelial-to-Mesenchymal transition (EMT) is a fundamental biological process essential 
for embryogenesis. However, in tumor progression, EMT is thought to be an initiative 
and vital process in the metastatic cascade. EMT occurs when epithelial cells undergo 
series of biochemical changes to lose their adhesive properties and cell polarity. In 
preference, they acquire a mesenchymal phenotype, which include increased migratory 
capacity, invasiveness and an increased production of extracellular matrix (ECM) 
components (31, 32). 
Cell adhesion 
In order for the epithelial cells to lose their adhesive properties, mediating proteins like 
cell adhesion molecules (CAMs) and cadherins are thought to be involved. Cadherins 
are calcium dependent transmembrane proteins that normally form adherence junctions 
and together with CAMs, “hook” cells into place with each other extracellularly (1, 31). 




specifically, gain of N-cadherin and loss of E-cadherin is considered to contribute to 
enhanced invasiveness (33, 34). Interestingly, a transfection of the E-cadherin gene into 
metastatic epithelial cells rendered them non-invasive (35). The exact mechanism 
behind this step in EMT is poorly understood, but one plausible hypothesis is that gain of 








Figure 2: The epithelial to mesenchymal transition involving loss of adhesive properties 
through a gain in N-cadherin and loss of E-cadherin. 
Intravasation and transport 
Further, cancerous epithelial cells must break free from the ECM components that 
restrain them. Special integrins of the cell adhesion family are thought to be involved in 
the loss of cell-ECM interaction, and matrix metalloproteases (MMP´s) in the 
degradation of ECM components (32). The tumor cells are able to exit through the 
basement membrane (absent in the lymphatic system) and enter the blood or lymphatic 
system via penetration between the endothelial cells. In the circulation, the transport is 
one-way in the direction of flow and in the blood stream they are accompanied by 





Extravasation and metastatic colonization 
The step for extravasation is the same as intravasation just in reverse. After successfully 
exiting though the endothelium and basement membrane, tumor cells can migrate into 
the surrounding stroma and form a secondary tumor at the secondary site (31). It has 
become evident that primary tumor cells orchestrate the development of a supportive 
microenvironment in secondary organs known as the “pre-metastatic niche” before the 
arrival of tumor cells. Tumor cells change the stromal host compartment through 
secretion of cytokines and growth factors which recruit and mobilize bone marrow 
derived cells to the pre-metastatic niche (36). When tumor cells arrive, the favorable 
microenvironment contributes to progressive growth and initiates angiogenesis that is 
essential for providing nutrients and oxygen (Fig. 3).  
 
 
Figure 3: The contribution of EMT on cancer progression and metastasis. With 
permission (31).  
Thus, the stromal microenvironment plays a major role in EMT which might demonstrate 
a more intricate tumor growth and progression that may challenge the current methods 
of treating metastatic cancer. Recent research has shown that hypoxic tumor cells 
condition pre-metastatic niches by secretion of factors that recruits certain myeloid cells 
and suppress natural killer cells (37). Hence, tumor cells and the stromal components 




1.4 Tumor hypoxia 
A common trait for most solid tumors is hypoxia, a condition where tissues are deprived 
of adequate oxygenation supply. Cells cannot normally survive without having a 
proximal vessel system that provides nutrients and oxygen, while removing waste 
products as well. The tumor vasculature is often disorganized and dysfunctional 
(irregular and sluggish blood flow) because the progressive tumor growth overrides the 
ability of the vasculature to adapt to the increasing oxygen demand (38). It also 
increases diffusion distances and induces tumor-associated anemia (39). Thus, without 
a functional vascular network, tumors are subjected to hypoxia. Solid tumors are, in fact, 
distinctively less oxygenated than the normal tissue from which they arose. Different 
areas of the tumor are subjected to different levels of hypoxia that would normally be 
toxic to cells, including tumor cells (40).  
Hypothetically, hypoxia may limit cell growth and contribute to decreased tumor 
progression. Nevertheless, tumor cells display an impressive ability to adapt and 
undergo genetic changes that facilitate continuous survival and proliferation in the 
hypoxic microenvironment (41, 42). Thus, hypoxia serve as a mediator for aggressive 
tumor growth and has been associated with malignant progression (42, 43). In particular, 
hypoxia has emerged as a primary inducer of the angiogenic switch, which previously 
mentioned is a hallmark of cancer development (44). It stimulates an up-regulation of 
pro-angiogenic factors such as hypoxia inducible factor 1 (HIF1). HIF1 activates 
vascular endothelial growth factors (VEGF), inducing blood vessel formation in tumors 
(40, 45). In addition, hypoxic stimulation of HIF1 activates a number of target genes 
involved in various other cell processes crucial for tumor biology (46). In relation to 
breast cancer, HIF1 has shown to be over-expressed and associated with aggressive 
tumor growth (47). Several signaling pathways involved in cell proliferation have also 
shown to be under the influence of hypoxia and HIF1 (48). Hypoxic conditions also 
prompt tumor cells to switch from aerobic to anaerobic metabolism. Cells deprived of 
adequate oxygen supply employ glycolysis as their primary mechanism of energy 




hypoxic conditions (50), tumor cells have acquired mechanisms to evade mediated cell 
death through induction of anti-apoptotic genes such as IAPS (51).  
In addition, associations between hypoxic tumors and increased metastatic ability have 
been established (52, 53).  Further, tumor hypoxia seem to predispose for increased 
tumor metastases through induction of EMT, where E- and N-cadherin plays a critical 
role (54, 55). Because the primary tumor cells and metastatic cells are similar 
morphologically, researchers have suggested that tumor cells regain epithelial properties 
at the secondary site, known as Mesenchymal-to-Epithelial transition (MET) (56). This 
transition has been linked to reduced tumor malignancy and invasiveness (57) .  
Another important feature of hypoxic tumors; reduced arterial oxygen tension (pO2), 
restricts organ and tissue function and can serve as an adverse prognostic factor. A 
study conducted by Hockel et al. (58) showed that hypoxic tumors (median 
pO2<10mmHg) in patients with cervical cancer had an increased risk of malignancy and 
worse overall survival. Moreover, a more recent study showed hypoxia to be a marker 
for metastatic disease in patients and that hypoxic tumors (median pO2<5mmHg) 
couldpredict progression-free survival of these patients (59). 
Initially, tumor hypoxia was studied due to its contribution to radiation and cancer 
chemotherapy resistance (60, 61). However, as ongoing research demonstrated its 
negative prognostic factor involving tumor cell adaptation, growth and metastasis, it´s 
now considered one of the best target options in cancer treatments. 
 
1.5 Hyperbaric Oxygen Treatment 
Hyperbaric oxygen (HBO) treatment is a method of enhancing tissue oxygenation by 
administering 100% pure oxygen at increased atmospheric pressure, using a hyperbaric 
chamber and treating for one or more consecutive sessions. Generally, the atmospheric 




HBO enhances tissue oxygenation by exploiting the physical properties of gases under 
pressure. Since hemoglobin saturation is around 97% at normal ambient pressure, HBO 
will not impact the total hemoglobin oxygen concentration. Instead, increased partial 
oxygen pressure (pO2) will push more oxygen into solution and expose tissues to 
elevated oxygen concentrations. This can be explained by Henry´s law:  
Henry´s law (Fomula 1) states that the amount of a given gas dissolved in liquid is 
directly proportional to its partial pressure in equilibrium with the liquid at a given 
temperature. 
 
Fomula 1: Henry´s law 
C = k x Pgas 
• C = The solubility of a gas at a given temperature in a particular liquid,  
• k = Henry´s law constant,  
• Pgas = the partial pressure of the gas 
 
 
According to Henry´s law, exerting elevated ambient pressure magnifies the amount of 
dissolved oxygen in blood plasma (63). Administering 100% pure oxygen at normal 
ambient pressure (1 bar) enhances the amount of dissolved oxygen in plasma from 3.2 
to 20.9 ml/1000ml blood. At 3 bar pure oxygen, the amount of dissolved oxygen in 








Table 1: Arterial oxygen pressures (pO2) and dissolved oxygen concentrations in blood 
plasma at different pressures (normobaric and hyperbaric). Modified from Sahni et al. 
(64) . 
Pressure % Oxygen pO2 (mmHg) ml dissolved O2 
/1000 ml blood 
1 bar 21% (normal air) 159 3.2 
1 bar 100% 760 20.9 
2 bar 100% 1520 44.4 
2.5 bar 100% 1900 56.2 
3 bar 100%  2280 68 
    
Resting tissue will excerpt 50-60 ml of oxygen per 1000 ml of blood assuming normal 
perfusion. Thus, increasing the pressure to 3 bar pure oxygen will hyper-saturate the 
blood with oxygen more than enough to meet resting tissue requirements without the 
contribution of hemoglobin (65). The dissolved oxygen even passes through obstructed 
areas where passage of red blood cells is limited. Additionally, the diffusion distance of 
oxygen through normal tissue is also considerably increased due to the increase in pO2 
(63). The amount of dissolved oxygen remains high for approximately 2-4 hours after 
administration of HBO treatment (66). Hence, HBO administration greatly enhances 
prolonged tissue oxygenation by elevated transport of soluble oxygen. 
HBO treatment is well established and considered a safe treatment for humans, without 
side-effects up to 2.8 bar (67). It is the primary line of treatment for decompression 
sickness, and The Undersea and Hyperbaric Medical Society (UHMS) has approved 




Table 2: Undersea and Hyperbaric Medical Society (UHMS) approved indications for 
hyperbaric oxygen treatment (68) . 
Air or gas embolism 
Carbon monoxide poisoning 
Clostridial myositis myonecrosis 





Necrotizing soft tissue infections 
Osteomyelitis 
Delayed radiation injury 
Compromised grafts and flaps 
Acute thermal burn injury 
Idiopathic sudden sensorineural hearing loss 
 
The beneficial mechanical effect of HBO treatment on decompression sickness and air 
embolism is reduction in bubble size by the increased pressure. For carbon monoxide 
poisoning, reversing hypoxia and competing with carbon monoxide for hemoglobin 
binding will treat the condition. In treatment of infections, HBO kills bacteria through 
recruitment of leukocytes and production of oxygen free radicals and facilitation of 
oxygen-dependent systems that induces certain antibiotics. HBO enhances wound 
healing by augmenting oxygen gradients next to ischemic wounds and induction of 
angiogenesis through oxygen-dependent ECM and collagen formation (62, 65). Even 
though HBO leads to vasoconstriction, blood flow significantly improves in ischemic 
tissue due to the increased oxygen carriage capacity in plasma. Thus, post-traumatic 
tissue edema is reduced, contributing to the treatment of crush injuries, compartment 
syndromes and burns (69). 
In summary, HBO treatment has therapeutic effects on many pathological conditions 




immune system. Perhaps the most positive effect comes from a reduction in hypoxia, 
enabling normal host responses to fight infection and disease.  
 
1.6 HBO treatment and cancer 
Our group has postulated a hypothesis saying that since tumor hypoxia represents 
increased malignancy through tumor progression and metastasis, reducing the hypoxic 
state of tumors could have opposing effects. 
However, because increased tissue oxygenation enhances ECM matrix formation, and 
induction of angiogenesis, it was feared that it would actually promote tumor growth. 
Interestingly, comprehensive studies on the effect of HBO treatment on normal tissue 
imply that tumors differ in response from normal tissue. In 2003, a review by Feldmeier 
et al. (70)  and Daruwalla et al. (71)  some years later, concluded that there is no 
evidence for HBO tratment enhancing tumor malignancy. In 2012, Moen et al. (72) 
supplemented the previous reviews. No existing research has indicated enhanced tumor 
growth nor enhanced recurrence after HBO treatment. Alternately, they presented 
evidence that HBO treatment has an antiproliferative effect on certain tumor types, and 
suggested that it could be effective in breast cancer treatment. It has become well 
documented that HBO treatment reduces tumor growth compared to controls in breast 
tumor models (73). In addition, Moen et al. (57) reported that HBOT induced MET and 
lead to less aggressive tumor behavior in an in-vivo 7,12-Dimethylbenzanthracene 
(DMBA) - induced breast cancer model. Furthermore, they also showed a metabolic shift 
away from glycolysis to oxidative phosphorylation after HBO treatment. Hence, on that 
background HBO treatment might inhibit or reduce tumor metastases in breast cancer. 
In essence, since metastatic spread of tumors is responsible for most breast cancer-
related deaths, it is of interest to evaluate whether HBO treatment could potentially 





2.   Aims 
 
The overall aim of the present study was to target the hypoxic tumor microenvironment. 
The following specific sub-aims were to: 
1. Investigate the effect of hyperbaric oxygen therapy on the malignant progression 
of human (MDA-MB-231) and murine (4T1 and 4T1L) breast cancer cells in vivo. 
 
2. Visualize potential metastases in vivo through biophotonic imaging 
 
3. Elucidate if hyperbaric oxygen treatment would influence major epithelial to 














3.   Methods and materials 
 
3.1   Cell lines 
A murine breast carcinoma cell line 4T1 and a human breast carcinoma cell line; MDA-
MB-231 (MDA-231) obtained from the American Type Culture Collection (Rockville, MD, 
USA) was used. A 4T1 cell line engineered to express the firefly enzyme Luciferase 
(4T1-L) to allow tracking and quantification through bioluminescence was also used. 
This cell line was a gift from Professor James Lorentz, University of Bergen, Norway. 
The murine 4T1 cell line was originally isolated from a spontaneous arising mammary 
tumor in a female Balb/cfC3H (Balb/c) mouse (74), while the MDA-231 cell line was 
originally isolated by pleural effusion from a 51 year-old Caucasian female with 
metastatic breast cancer (75).  
Both cell lines are well characterized and known to metastasize to sites as in human 
breast cancer (lungs, lymph nodes, liver, bone and brain) via the haematogenous route 
in mice, making it a representable model for studying human breast cancer behavior (74, 
76).  
The 4T1 and 4T1-L cells were cultured with RPMI-1640 medium, and the MDA-231 cells 
were cultured with Dulbecco´s Modified Eagles Medium (DMEM-D5671) (both from 
Sigma-Aldrich, Steinheim, Germany). Both mediums were supplemented with 10% 
Foetal Bovine Serum (FBS), 2% L-glutamine, 100 units/ml penicillin and 100 /ml 
streptomycin (all from Sigma-Aldrich, Steinheim, Germany). Cells were cultured with 
their respective mediums as a monolayer in 75cm² standard tissue flasks (NUNC, 
Roskilde, Denmark), kept in a humidified incubator at 37°C with 5% carbon dioxide 
(CO2), 95 % air and seeded until 75% confluence before the medium was changed. The 
standard cell culture work was performed with trypsin, Dulbecco´s Phosphate Buffered-




laminar flow bench with a high efficiency particulate air (HEPA) filter in a sterile 
environment. 
 
3.2   Animal models 
A total of 24 female Balb/c (Taconic Biosciences, Ejby, Danmark) mice with an initial 
weight ranging from 18 to 27 grams were used as model for the 4T1 and 4T1-L cell line. 
A total of 12 female non-obese diabetic/severe combined immunodeficient gamma 
(nod/scid) mice (Jackson Laboratory, Bar Harbour, ME, USA) were used as a model for 
MDA-231 human mammary cancer cell line. Their weight ranged from 21 to 24 grams. 
All experiments were performed when the mice were approximately 6-8 weeks old. 
All mice were housed in intraventilated cages (maximum 5 in each) (Makrolon IV, 
Techniplast Gazzada, S.a.r.l., Buggigiate, Italia) with a room temperature of 21° degrees 
and air humidity held between 40-60% at the animal facility at University of Bergen. The 
mice were exposed to a light/dark cycle at 12/12 hours. They had a fixed diet consisting 
of pellets (Special Diet Service, Witham Essex) and water. The mice were identified by 
having their tails labeled with a permanent marker. 
All experiments with animals in this study were performed in accordance with the 
Norwegian Animal Research Authority and approved by the local ethical committee 
(project nr. 20157368). The number of animals was minimized to comply with the ethical 
committee guidelines. 
 
3.3   Anesthesia 
All mice were anesthetized with Isoflurane (Isobal®Vet, Orion Pharma Animal Health, 




during all cell injections and tumor size measurements. During gas-anesthesia the 
mouse was placed in a plexiglas chamber flushed with anesthetic gas at a rate of 5 
l/min. When the mouse was satisfactory anesthetized the dose was reduced to 2 L/min. 
The mouse was then placed on a heating pad which kept the body temperature at 37 ºC 
± 0.5 ºC and anesthesia was supplied by a nozzle to the nose and mouth area.  
To make sure that the mouse was completely anesthetized, the contraction reflex was 
tested by pinching the sole of the back foot with a tweezer.  
All mice were sacrificed under anesthesia by cervical dislocation (all 4T1-L mice after 
optical imaging) or by CO2. 
 
3.4   Preparation of cells before injection 
Using the cell nucleocounter SCC-100 and a nucleocassette (Bergman-Nucleocounter-
Chemometec, Allerød, Denmark) the number of cells/mL solution was identified as 
follows: 
All cells from each flask were trypsinized into a single cell suspension. In accordance 
with the manufacturer’s instructions, 200 μl was extracted from the cell suspension and 
mixed with 200 μl of buffer A and B (Bergman-Nucleocounter-chemotech, Allerød, 
Denmark). Buffer A is a lysis reagent with a pH of 1.25. It acts by disrupting the plasma 
membrane, leaving the nuclei susceptible to staining with fluorescent dye and propidium 
iodide (PI). Buffer B is a stabilizing reagent that raises the pH in order of DNA staining to 
be as efficient as possible. 
The suspension was vortexed (MS2 Minishaker, Apendoorn, Netherlands) directly 
before being loaded into the nucleocassette. Automatically, the cassette uploads 50 μl of 
the cell suspension and mixes it with PI. By staining the nuclei of cells, the 




The total amount of cells/ml suspension obtained from the nucleocounter was multiplied 
by three due to dilution factors caused by reagents A and B. The rest of the cell 
suspension was centrifuged (Eppendorf Centrifuge 5810 R, Hamburg, Germany) at 990 
rounds per minute (rpm), at 10°C for 4 minutes before culture medium was removed 
from the centrifuged cells. Calculated amount of PBS was added to obtain 5 x 105 cells 
per 0.15 ml suspension according to this formula: 
 
Formula 2: Added PBS  
Total amount of cells * 0,15 ml 
500000 cells 
 
3.5   Establishing tumors 
Each mouse was injected with 5 X 105 cells, in a 0.15 ml suspension subcutaneously 
into the lower mammary fat pad at the right side at day 1. At this point, all mice were 
divided into two groups; control and HBO. The two groups were kept separate 
throughout the experiment. After 8 days, the 4T1 cell line had formed measurable 
tumors in all mice (7/7), while only a few tumors from the MDA-231 cell line were 
noticeable (2/6). 
 
3.6   Hyperbaric oxygen treatment 
A 27 l cylindrical pressure chamber (Oxycom 250 ARC, Tampere, Finland) with an inner 




When undergoing treatment, mice were placed in the pressure chamber. The chamber 
was locked airtight and O2 concentration was monitored by an oxygen cell. Before each 
treatment, a flush phase with supply of pure O2 for ~15 minutes was conducted with no 
increase in pressure. When 98% O2 was reached the chamber was pressurized 
(compression phase) steadily to 2.5 bar for 10-15 minutes. This pressure was 
maintained for 90 minutes in which the chamber atmosphere was flushed for 5 minutes 
every 10 minutes to ensure an atmosphere of >97 % O2 at all times. After treatment, the 
chamber was decompressed slowly to 1 bar over a period of 10 -15 minutes. 
Mice undergoing treatment were exposed to HBO from day 7 (4T1 and 4T1-L) or 8 
(MDA-231) and every third day until termination of the experiment (day 22 and 33 for 








3.7   Tumor growth measurement 
Tumors were measured externally by a caliper immediately following HBO treatment. 
The tumor shape and approximate size were schematically drawn on day one to ensure 












Figure 5: Schematic drawing of a mouse with primary mammary tumor used for 







The tumor was measured bidirectional assuming that the tumor had a cylindrical shape. 
Tumor volume was estimated according to the formula: 
  
Formula 3:                               
Tumor volume (mm³) = (π/6) x (a²) x (b) 
 
- where a is the shortest and b is the longest transversal diameter of the tumor.  
All mice were weighed and observed throughout the experiments to get an indication on 
any substantial health problems. 
 
3.8   Optical Molecular Imaging 
An optical imager (eXplore Optix™, Advanced Research Technologies Inc., Quebec, 
Canada) was used to visualize primary tumor tissue and metastasis in vivo through the 
bioluminescent enzyme luciferase present in tumor cells. Mice with 4T1-Luciferase cells 
were injected intraperitoneally with D-luciferine (150 mg/kg) (Sigma-Aldrich, Steinheim, 
Germany) diluted in saline (25mg/ml) and anesthetized using isoflurane as mentioned 
previously (section 3.3). Following ten minutes post injection, the mouse was positioned 
on its back with extremities fastened to the ground by tape in the optical chamber with a 
set temperature (35°C). Manual adjustments were set as follows: Integration time: 0.3, 
region of interest (ROI): Polygon (scanning area was set by manually drawing around 
the area of interest on the mouse), Scan resolution – 1.5 mm. The intensity value (NC) 
had to be above 100 or otherwise excluded as background noise. Immediately after 
acquisition, 2D images were visible. At the experimental endpoint, mice were euthanized 
by cervical dislocation whilst under anesthesia and primary tumors were immediately 




node, liver, spleen, kidney, primary tumor and bone) were harvested and imaged in a 
petri-dish with 10% formalin for metastasis evaluation. Finally, organs were prepared for 
fixation (described in section 3.9). 
 
3.9   Isolation of organs/tissues 
On the day of termination mice were euthanized (previously described in section 3.3) 
and the following organs/tissues were dissected out: primary tumor, lungs, axillary lymph 
node, liver, kidney and bone (part of femur and tibia). The lungs were fixated with 1ml of 
Bouin´s solution (Gurr BDH Chemicals Ltd., Poole, UK) by cutting the trachea open with 
a pair of small scissors and injecting the solution into the lungs with a thick needle were 
the tip was cut off. Lungs were placed in Bouin´s solution for 24 hours and then in 70% 
ethanol (Sigma-Aldrich, Steinheim, Germany). The ethanol was changed every other 
day until it became clear and no longer yellow. The tumors were quickly snap frozen in 
liquid nitrogen and stored in a -80°C freezer (Sdanyo, MDF-C52V) until further use. The 
bones were placed in 10% ethylenediaminetetraacetic acid (EDTA) solution (pH 7,2) 
(Sigma-Aldrich, Steinheim, Germany), for decalcification and changed 3 times a week 
until the bones were soft enough to cut into sections. The rest of the organs were fixated 
in 10% formalin solution (VWR Chemicals, Leuven, Belgium) for one day. All 
organs/tissues were kept in 15 or 50 ml Falcon tubes. The samples were delivered to 
Anne Nyhaug at the Molecular Imaging Center (MIC) at the University of Bergen for 
paraffin fixation, hematoxylin and eosin (H&E) staining and slicing into 4 μm thick 





3.10   Estimation of metastasis 
The number of metastases and metastatic area (mm²) on isolated organs were 
determined by using a light microscope (4 x 10) and camera (Digital Sight, Nikon 
Corporation, Tokyo, Japan) on paraffin embedded sections stained with hematoxylin and 
eosin. The software, NIS Elements Confocal 9.0, from Nikon was used. The area of 
metastases was manually drawn around each cluster of metastatic cells and the 
program automatically calculated the area (mm²). Due to time limitations, only the lungs 
and liver were examined for metastasis. For each organ, 4 sections at different depths 
were chosen for metastasis detection. 
 
3.11   Western blot 
3.11.1 Tissue preparation 
Frozen tumors were cut with a scalpel about 2/3 into the middle, and a cross section of 
tumor tissue (approximately 50 mg) was isolated and kept on ice. Exactly 1ml of 
denaturing lysis buffer (provided by Tonje Sønstevold, see Appendix A for more details) 
was added to a tube with homogenizing beads (Bertin Technologies, France). 
Tumor pieces were added to the mixture and placed in a tissue homogenizer 
(Precellys® 24, Bertin Technologies, France) (program 2: 6800 rpm -3x, 10-30 sec.) at 
4°C and incubated on ice for 45 minutes. After completion, the samples were visualized 
to ensure complete lysis of the tumor pieces. The lysate was subtracted and centrifuged 
at 12000 rpm for 10 minutes at 4°C (Eppendorf 5415R, Hamburg, Germany). The 
supernatant was collected, aliquoted into 3 x 200 μl samples and stored at -80°C. The 





3.11.2 Protein concentration assay 
The protein concentration was determined by a Bicinchoninic acid (BCA) protein assay 
kit, (Pierce™, Thermo Scientific, Rockford, USA) containing reagent A, reagent B and 
bovine serum albumin standard ampules to establish sample protein concentration. 
In order to get the samples to comply with the standard curve, they had to be diluted in 
double distilled water (ddH2O) (dilution factor 1:50). Five μl of sample were added to 245 
μl of ddH2O. Albumin standards were diluted in ddH2O and prepared as follows: 2 
mg/ml, 1 mg/ml, 500 μl /ml, 250 μl /ml, 100 μl /ml, 50 μl /ml and 25 μl /ml. Calculated 
amount of master mix combining reagent A and B was prepared (ratio 50:1) accordingly: 
 
Number of standards x number of samples x 3 repetitions x 200 μl per well  
= Amount of master-mix 
 
To each well on a 96-well plate, 195 μl of master-mix was added. Albumin standards 
and samples were loaded (5 μl) in triplets (Fig. 6). The plate was incubated at 37°C for 






Figure 6: Overview over albumin standards and lysate samples on the 96-well plate. 
 
3.11.3 Absorbance reading 
The absorbance was estimated using a microplate reader spectrophotometer at 562 nm 
with the software SoftMax® Pro (VersaMax™, Molecular Devices, Sunnyvale, CA, 
USA). Samples that were obviously not correct (e.g. loading error) were masked. 
Samples were also checked for severely deviating concentration (optical density) values. 
A coefficient of variation (CV) value (measure of dispersion) over 10.0 was considered 
an indication of deviating concentration values that needed to be corrected. Since each 
sample was loaded three times, we could check if one value deviated significantly from 
the others, and thus masked. We corrected four and five deviated values from the 4T1 





3.11.4 Gel electrophoresis 
The protein lysates were selected (control and HBO) and collected from the -80°C 
freezer and thawed on ice. New 1.5 ml Eppendorf tubes with 30 μl of protein lysate were 
centrifuged for a few seconds before diluted in 10 μl loading buffer (XT Sample Buffer, 
Bio-Rad laboratories, California, USA) The proteins were denatured by “boiling” at 95°C 
for 5 minutes (Dri-Block® DB-2A, Techne, Cambridge, UK) before briefly spun down. 
The proteins were separated on premade 12% protein gels (Precice™, Thermo 
Scientific, Rockford, USA) in 500ml of Tris-HEPES-SDS running buffer (BuphJ™, 
Thermo Scientific, Rockford, USA). The samples were loaded next to a marker 
(Precision Plus Protein™, Dual Color Standards, Bio-Rad Laboratories, Mϋnchen, 
Germany) and a normoxic HCC cell lysate (gift from Maria Tveiterås, University of 
Bergen) as positive control was used in well 12. The samples were added (10 μl) with a 
control in well 2, HBO in well 3, control in well 4 and so on. The electrophoresis box was 
connected to an electrophoresis power supply (PowerPack™, Bio-Rad laboratories, CA, 
USA) and run for 10 minutes at 95 V and 60 minutes at 110 V. 
 
3.11.5 Transfer and blocking 
The gel with separated proteins was transferred to a membrane using gel transfer stacks 
(cathode, anode and sponge) in a gel transfer device (all from Invitrogen iBlot™, Life 
Technologies, Carlsbad, CA, USA) using program p3 for 7 min. Membranes were 
blocked with I-block buffer (provided by Tonje Sønstevold, University of Bergen, see 
Appendix A for details) for 1 hour and 30 min at room temperature in order to impede 
unspecific binding of primary antibody. Thereafter, the membranes were placed in 50 ml 
Falcon tubes before adding the primary antibody and diluted in I-block to achieve a final 
volume of 2 ml per tube (see dilution factor for each antibody). Rabbit anti-mouse E-
cadherin (ab53033, dilution factor 1:800) and rabbit anti-mouse N-cadherin (ab76057, 




primary antibodies. The tubes containing the membranes, I-block and antibodies were 
incubated over night at 4°C.  
The following day the membranes were washed 3 times x 5 minutes with Tris buffered 
saline-Tween® (TBS-T) (see Appendix A for more details) to remove unbound primary 
antibody and to prevent sodium azide (NaN3) in I-block buffer from reacting with 
peroxidase in the secondary antibody. The membranes were moved from the tubes to 
small containers together with 10 ml of mixed secondary antibody and TBS-T (dilution 
factor 1:5000) and incubated for 2 hours at room temperature. Goat anti-rabbit IgG 
Horse radish peroxidase (HRP) (ab97051, Abcam, Cambridge, UK) was used as 
secondary antibody. 
 
3.11.6 Protein detection 
Membranes were washed 2 x 5 minutes with TBS-T and 1 x 5 minutes with 1xTBS (see 
Appendix A for more details) prior to protein detection. Development of membranes 
were performed with West Pico Chemiluminescent substrate (SuperSignal®, Thermo 
Scientific, Rockford, USA) by mixing peroxide solution and luminol enhancer solution 
with the ratio 1:1. The membranes were put on a plastic cover and the mixture was 
poured over the membrane with a pipette. The protein bands were visualized 
(ChemiDoc™ XRS+, Bio-Rad laboratories, CA, USA) and densitometry was performed 
using the software Image Lab™ for band quantification. 
The membranes were reprobed adding rabbit anti-mouse β-actin (ab15263, dilution 
1:5000, Abcam, Cambridge, UK) for protein loading control with the procedure as 
mentioned above. 
After development, the visible bands from MDA-231 tumor lysates were quantified into 
optical intensity values for statistical analyses and comparison between HBO treatment 
and control group. Due to no observable difference in protein expression we decided not 





For statistical analysis, unpaired two tailed t-test or Wilcox test was used to analyze 
statistical differences between the two groups. Results were accepted as statistically 
satisfactory when p<0.05. Standard deviations or standard errors of means are indicated 
in Figures and Tables. The software IBM SPSS 23.0 for Windows was used for 
statistical analyses, SigmaPlot 9.0 (Systat Software) for creating figures and Image-Lab 















4.   Results 
 
4.1   Tumor growth 
The average 4T1 tumor volume showed unexpectedly, no significant difference between 
the HBO-treated and non-treated (control) group, neither at day 7 (p<0.13) or at day 22 
(p<0.82). The HBO-treated group measured an average tumor volume of 244±28.5 mm3 
at day 7 compared to 171±35.0 mm3 in the control group (Fig. 7). Average tumor volume 
increased with 815 mm3 in HBO-treated and 921 mm3 in control mice during the course 










Figure 7: The effect of hyperbaric oxygen (HBO) treatment on 4T1 breast tumor growth 
in treated (n=7) and control (n=7) balb/c mice during a period of 22 days. Mice were 
treated with 2,5 bar pure oxygen for 90 minutes, every third day. Data are represented 




The average 4T1-L tumor volume was significantly lower in HBO-treated compared to 
controls at day 16 (p<0.04), day 19 (p<0.02) and the last day (p<0.04).  The HBO-
treated group measured an average tumor volume of 120±10.5 mm3 at day 7 compared 
to 198±66.1 mm3 in the control group (Fig. 8). Average tumor volume increased with 419 













Figure 8: The effect of hyperbaric oxygen (HBO) treatment on 4T1-Luciferase breast 
tumor growth in treated (n=5) and control (n=5) balb/c mice during a period of 33 days. 
Mice were treated with 2,5 bar pure oxygen for 90 minutes, every third day. Data are 









The average MDA-231 tumor volume was significantly lower in HBO-treated compared 
to control nod/scid mice at day 30 (p<0.002), and day 37 (p<0.012), but not at day 53 
(p<0.15).  The HBO treated group measured an average tumor volume of 63.9±12.3 
mm3 at day 30 compared to 160.3±20.4 mm3 in control mice (Fig. 9). Average tumor 
volume increased with 397 mm3 in HBO and 532.3 mm3 in controls during the following 
23 days. Tumors (n=12) were measured from day 8, however, due to the low number of 




Figure 9:  The effect of hyperbaric oxygen (HBO) treatment on MDA-231 breast tumor 
growth in treated (n=6) and control (n=6) nod/scid mice during a period of 53 days. Mice 
were treated with 2,5 bar pure oxygen for 90 minutes, every third day. Data are 






4.2   Metastasis 
Macroscopic surface metastases were found in the lungs of all tumor models (Fig. 10). 
However, due to unfamiliar appearance and resemblance to lymphocyte tissue, we had 






Figure 10: A representative picture demonstrating 4T1 surface metastases in the lung is 
shown. 
Paraffin-embedded, H&E stained 4T1, 4T1-L and MDA-231 sections of various organs 
were used for metastasis number and area estimation. Histological examination of 4T1, 







4.2.1 Lung metastasis 
The 4T1 tumor model showed no statistical difference in the number (p<0.27) and area 
(p<0.4) of lung metastases between the HBO-treated and control group. Only 5 out of 7 
HBO-treated cases developed metastases, and 4 out of 6 of the controls displayed 
metastases in the lungs. One of the control mice (mouse nr. 4) had to be sacrificed at 
day 13 for ethical reasons due to severe tumor growth. 
The average area of 4T1 metastases observed in the HBO-treated group was 6.3±3.5 
mm2 compared to 8.4±10.2 mm2 for the control group (Fig. 11). The high standard 



























Figure 11: The effect of hyperbaric oxygen (HBO) treatment on the metastatic potential 
of 4T1 tumor cells in vivo after 22 days. Histomorphometric quantification of metastasis 
number (A) and area (B) in H&E stained lung sections in treated (n=5) and control (n=4) 
balb/c mice are shown. Data are represented as Mean ± SD. A representative lung 








The 4T1-L tumor model showed a significant lower area (p<0.05) but not number (p<0.6) 
of metastases in the HBO-treated compared to control group. The average area and 
number of 4T1-L lung metastases were 1.3±0.4 mm2 and 54.0±10.2 in HBO compared 










Figure 12: The effect of hyperbaric oxygen (HBO) treatment on the metastatic potential 
of 4T1-L tumor cells in vivo after 25 days. Histomorphometric quantification of 
metastasis number (A) and area (B) in H&E stained lung sections in treated (n=5) and 
control (n=5) balb/c mice are shown. Data are represented as mean ± SD. *p<0.05. A 








The MDA-231 tumor model showed a significant lower number (p<0.04) and area 
(p<0.02) of metastases in the HBO-treated compared to control group. The average 
number and area of observed MDA-231 lung metastases were 107±95 and 0.5±0.6 mm2 
in HBO compared to 273±142 and 9.5±13.6 mm2 in control group, respectively (Fig. 13). 
 







Figure 13: The effect of hyperbaric oxygen (HBO) treatment on the metastatic potential 
of MDA-231 tumor cells in vivo after 53 days. Histomorphometric quantification of 
metastasis number (A) and area (B) in H&E stained lung sections in treated (n=5) and 
control (n=4) balb/c mice are shown. Data are represented as mean ± SD. *p<0.05. A 







4.3 In vivo optical imaging 
Bioluminescent 2D-images showed that the 4T1-L primary tumors of HBO-treated mice 
were significantly smaller as also indicated by tumor volume and weight at the last day 
(day 33). We were unfortunately unable to observe any metastases to distant organs, 
neither in situ (Fig. 14) or after imaging the organs separately. This is contrary to the 










Figure 14: In vivo optical images of bioluminescent 4T1-Luciferase tumor cells after 
hyperbaric oxygen (HBO) treatment (control- upper panel, HBO- lower panel) in balb/c 
mice after 33 days. The relationship between color and light intensity (NC) was 









4.4 Protein detection 
Western blotting was performed using primary tumors to detect levels of N-cadherin and 
E-cadherin expression. Immunoblots from 4T1 and 4T1-L tumor lysates showed no 




Figure 15: E-cadherin (A) and N-cadherin (C) expression is unchanged in western blots 
of 4T1 (n=5) and 4T1-L (n=5) primary tumors after HBO treatment compared to control, 
showed by one representative immunoblot. 




Immunoblots from MDA-231 tumor lysates indicated a downregulated N-cadherin 
expression in HBO-treated tumors. However, no expression differences in E-cadherin 
between the two groups were observed. The downregulated N-cadherin in HBO-treated 
tumors was confirmed by volume density data and statistical analyses showed a 
significant difference (p<0.021) (Fig.16). 





Figure 16: MDA-231 tumors constitutively express E-cadherin (A) and N-cadherin (C) in 
western blot lysates in both groups. The expression of E-cadherin (B) and N-cadherin 
(D) when adjusted according to loading control (β-Actin) in control (n=5) and HBO-
treated (n=5) is also shown. Data are represented as mean ± SD.*p>0.05 
* 
* 





The strengths and potential weaknesses of the applied methods concerning this study 
will be discussed in the following section. Thereafter, a general discussion of the results 
and summarized conclusion will be presented before discussing future perspectives. 
 
5.1 Methodological aspects 
5.1.1 Cell lines  
There are several reasons why the murine 4T1 and the human MDA-231 cell lines were 
chosen for this study. First of all, they are both easily injected into the murine mammary 
gland, being the anatomically correct site for a primary tumor to develop (orthotopic site) 
(77, 78). The mammary gland is also the favorable growth site due to appropriate 
dissemination and expression of the metastatic phenotype (79). Both cell lines are highly 
aggressive and do metastasize. 
However, it is worth mentioning that metastatic dissemination occurs via the 
hematogenous route as opposed to the initial spread to local lymph nodes via the 
lymphatic system in human breast cancer (79). Nevertheless, both cell lines metastasize 
to the same sites as it would in human breast cancer. 
The use of 4T1 cells have increased recently because of the high tendency to 
spontaneously metastasize from the primary tumor multiple distant sites as it would in 
human breast cancer (77). Due to unexpected tumor growth and metastatic results from 
the 4T1 tumor growth experiments (discussion below), the use of luminescent 4T1-L 
cells was implemented. There was not enough time to investigate all organs for 




metastases much quicker.  
The use of human tumor cell lines is however generally more desirable. Richmond et al. 
(80) stated that: “If one wants to know whether a patient’s tumor will respond to a 
specific therapeutic regime, one must examine the response of that human tumor, not a 
mouse tumor”. Human breast tumor cells have previously shown to have a slow tumor 
take rate and poorly replicate the metastatic process mice (81). However, the MDA-231 
xenograft models have shown to display an aggressive phenotype and reliably form 
distant metastatic tumors even when injected into the orthotopic site (78). We believe 
that both cell lines serve as excellent models for studying TNBC behavior. 
The 4T1 cells were cultured in RPMI-1640 media supplemented with FBS, L-glutamine, 
penicillin and streptomycin to achieve optimal growth conditions. This combination is 
commonly used for 4T1 cells in research (74, 82). The MDA-231 cells were cultured in 
DMEM medium also supplemented with FBS, L-glutamine, penicillin and streptomycin 
for optimal growth conditions which is supported by literature (82). 
The number of cells injected were determined by previous pilot studies performed by our 
research group, and by previous literature (83). We concluded that 5 x 105 cells were 
adequate for inducing primary tumor growth in an ethical perspective for a time frame 
long enough for metastasis to occur.  
 
5.1.2 Animals 
While no single animal model can recapitulate all the human cellular and molecular 
complexities in cancer, a tremendous gain in elucidating breast tumor progression is due 
to mouse models. Furthermore, tumor-host interactions are complex and not possible to 
investigate using in vitro studies. As previously mentioned, understanding the metastatic 
process and metastatic sites from a clinical standpoint is paramount since most cancer-




an early stage will develop metastatic tumors at some point (26). Creating tumor models 
in animals mimicking human breast cancer behavior as similar as possible expands that 
understanding and improve treatment options without potentially putting human patients 
at risk. Mice are advantageous in research due to anatomical and physiological 
similarities to humans and they can be bread in large quantities in a short matter of time. 
They are cheap, easy to breed and handle, they don’t require too much space and are 
usually genetically homogenous. Mouse models are also used for predicting efficacy and 
toxicities of cancer therapeutics before clinical trials (79). 
4T1 cells are originally derived from a spontaneous murine mammary tumor of a balb/c 
mouse and therefore grow rapidly when injected into the fat pad of a syngeneic animal 
(74). Establishment of 4T1 tumor allografts in balb/c mice has been widely used in 
research and supported by literature (76, 77, 82).  
MDA-231 cells were originally derived by pleural effusion from a breast cancer patient 
(75) and only immunodeficient mice will not reject the foreign material. Nod/scid mice 
are deficient in T- and B- lymphocytes as well as NK cells and thus avoid developing an 
immune response to human cells, like MDA-231. Previously, human tumor cells have 
replicated and metastasized poorly in mice, making it difficult to study human breast 
cancer behavior (81). Studies have been dependent on subcutaneous and tail vein 
injection of cells to achieve tumorigenesis, and hence, mimicking of human tumor 
progression and metastasis in an adequate way was not possible (81, 84). In addition, 
when injected orthotopically the primary tumor had to be surgically removed when grown 
to a considerable size and at that point, several complications arose (84). Nevertheless, 
the more severely immunocompromised nod/scid mouse have been successfully used 
to study human breast cancer metastasis, when injected orthotopically without removing 
the primary tumor (78).  
Some researchers state that murine tumor models are the optimal model system for 
studying malignant progression and responses to cancer therapeutics because they 




tumor-host interaction (76). Others emphasize the importance of human cancer cells in 
clinical research to obtain reliable results (80).  
Other focuses in animal models have been on understanding the tumor-stroma 
relationship. Stromal cells and the extracellular environment impact tumor growth, 
vascularization and the metastatic potential. Murine tumor cell models often display a 
more aggressive phenotype similar to the behavior in cancer patients. Given the 
importance of the tumor microenvironment, syngeneic models such as the 4T1 model 
allow interactions between a normal immune function and tumor behavior (76). As the 
stroma between the two mouse models differ from each other, tumor progression and 
development could also differ. Nod/scid mice lack a functional immune system and thus 
present difficulties in analyzing the effects of stroma on tumor cell growth.  
We believe that combining murine and human tumor models in mice for studying human 
breast cancer is the optimal way of obtaining reliable results.  
It is important to know that human and mouse tumorigenesis differ in response to some 
physiological aspects. They are much smaller, grow quicker and the kinetics of 
carcinogenesis and the final size of the tumor will be markedly different. Many cell-




In this experiment, Isoflurane combined with N2O and O2 gas was used. Gas anesthesia 
is the preferred option when sedating animals and is commonly used among 
veterinarians. Gas anesthesia was used in the experimental protocols because the 
experimental procedure didn’t require much time and the animals recovered quickly from 




Isoflurane has been indicated to interfere with the vascular system and decreases blood 
pressure as well as increase heart rate. However, a low dose of 2 l/minute was used in 
this study and this is not believed to affect the outcome of the results. Because it is a 
vasodilator, central body temperature generally decreases, hence the use of a heating 
mat maintaining the body temperature of the mice at approximately 37°C throughout the 
procedure. 
 
5.1.4 Tumor growth 
Tumor growth was assessed by estimating the tumor volume using a caliper and a 
standard formula. This procedure is not optimal since only measuring the tumor 
externally will not generate an exact volume. This is because the surrounding skin will 
always be implemented. To accurately measure the volume, the tumor has to be 
dissected out, and this can only be performed at the end of the experiment eliminating 
the ability to follow growth over time. The tumors were dissected out and weighed at the 
last day to compare with our growth measurements. However, it was impossible to 
remove the whole primary tumor due to local infiltration and tendency for cells to invade 
the limb area. Therefore, this was not a better option when using these invasive tumor 
models. 
By using the caliper method, we are also able to compare results with previous studies 
at our laboratory. All tumors are also measured in the same manner, making any 
differences between the groups apparent. In addition, some claim that this method is 
subjective and difficult to accurately reproduce. To justify this, all measurements in the 
present study were performed by the same operator and by not looking at the previous 
measurements, any irregularities would affect both experimental groups equally. Thus, 
any subjective inaccurate measurements would still generate acceptable results.  




formula assumed all tumors had a cylindrical shape. Again, this applied to tumors in both 
experimental groups and any differences would therefore be equally measured. Both 
4T1 and MDA-231 tumors displayed varied differences in size in both HBO and control 
groups. Since accurate number of cells was injected into the same site under equal 
conditions, the reason for this is uncertain. 
 
5.1.5 Hyperbaric oxygen treatment 
The reasoning for choosing HBO treatment has been described previously (section 1.5). 
Studies have shown that the reduction in tumor growth was inversely correlated to 
enhanced oxygen pressure (86). Furthermore, 2 bar HBO exposure lead to induction of 
MET and changes in metabolism in DMBA-induced breast cancers (57). Recent studies 
have also investigated the effect of 2.5 bar HBO treatment on genetically engineered 
4T1 tumor cells in vivo showing a tumor inhibitory effect (87). Other studies have also 
reported reduced tumor growth compared to controls from hyperoxic treatment 
exposures lasting for 90 minutes (73, 87). Since HBO treatment up to 2.5 bar for 90 
minutes each exposure is considered safe and clinically relevant, our experimental 
protocol included administration of HBO at 2.5 bar to potentiate the beneficial effects on 
tumor progression and metastasis.  
Toxic effects of hyperoxia have been observed in the central nervous system and lungs 
at doses above 2.5 bar or over daily exposures lasting several weeks. The toxic effects 
included seizures, visual changes, sweating, muscle twitching, coughing, pulmonary 
fibrosis and shortness of breath (88). As expected, no symptoms of toxicity could be 
observed during exposures and the course of the experiment, indicating that the 
treatment protocol was safe. However, insufficient inner ear equilibration from 
compression and decompression could cause unpleasantness and even more serious 
side effects. Thus in the present study, both compression and decompression was 




and shook their heads during the pressure changes indicating a slight discomfort. 
Decompression/compression was then slowed down even more until they started 
behaving normally.  
There is a small risk of developing fire in a pure oxygen atmosphere and adequate 
precautions such as keeping the chamber litter- and oil-free was therefore undertaken. 
 
5.1.6 In vivo optical imaging 
Bioluminescent-based optical imaging was chosen for this study due to the ease and 
non-invasive monitoring of cancer progression in animal models. Due to the unexpected 
tumor growth results from 4T1, we wanted to implement 4T1-L cells to possibly uncover 
any metastases in vivo in addition to evaluate the response of another 4T1 tumor model. 
Another huge benefit of this method is the continuous analysis of changes in tumor 
progression over time without sacrificing the animals (85). This new approach is widely 
used instead of autoflourescent-based imaging because external excitation from tissues 
are avoided leading to background-free imaging conditions (89).   
The luciferase-expressed tumor cells (4T1-L) catalyze the oxidation of luciferin (injected 
10 minutes prior to imaging) to oxyluciferins and yellow-green light photons are released 
in the emission spectrum (530-640 nm) (90). The reaction was recently estimated to only 
produce a 40% quantum yield, yet sufficient enough to produce a detectable light (91). 
There are several other bioluminescent reporter proteins, all with advantages and 
disadvantages. The firefly luciferase and D-luciferin substrate have a high sensitivity and 
low signal-to-noise ratio. There is also a quantitative correlation between signal strength 
and signal numbers and different colors allow multi-component monitoring. However, it 
requires exogenous luciferin injection and fast consumption of luciferin can lead to an 
unstable signal  




The optical properties within a biological tissue sample are dependent on several 
factors. The location and number of functional luciferase cells and the flux of photons 
from them within the sample will somewhat differ and impact the final image (92). 
Nevertheless, scattering and bioluminescent absorption can be reduced by increasing 
the wavelength which allows us to measure greater amounts of signal intensity (89).  
The route of substrate (D-luciferin) injection should also be considered because it can 
have influential effects on the bioluminescent signal. Intraperitoneal injection was 
chosen for this study as it is convenient and widely used in this kind of research. 
However, D-luciferin must absorb across the peritoneum to reach the luciferin-expressed 
tumor cells. Absorption rate can vary and lead to luminescent signal variations, thus 
impacting the reproducibility of the results. Intravenous injection of D-luciferin has shown 
to offer better repeatability and sensitivity than intraperitoneal injection in small tumors 
(93). Operator error can also include unintentional injection into the bowel which 
produces a low or undetectable signal. Intraperitoneal injection also produces a lower 
signal than subcutaneous injection in subcutaneous tumors, but it can also over-
estimate tumor size localized intraperitoneally due to the direct contact of D-luciferin and 
luciferase-expressed tumor cells (94). One must therefore carefully select the 
appropriate route of injection depending on the location and type of tumor cells inside 
the animal. For subcutaneously grown breast cancers, we believe that intraperitoneal 
injection with D-luciferin was the appropriate method. 
 
5.1.7 Histological quantification 
The other method of evaluating metastasis in different tissues was to stain paraffin-
embedded sections of organs and tissues with H&E and assess number and area of 
metastases under a light microscope. This method is very time consuming, and as only 
4-5 sections were used, the whole organ could not be assessed. It does however, 




counting and outlining metastases could potentially deviate from specific actual values 
however, the same investigator was used to assess all samples in this study to assure 
equal measurements.  
In this experiment, metastasized tumor cells could easily be distinguished from normal 
cells in lung sections from MDA-231 and 4T1 tumor models which leaved less room for 
speculation and inaccurate results. However, the 4T1-L tumor model was more difficult 
to assess. The metastatic lesions were not easily distinguished from normal tissue and 
infiltrated lymphatic tissue, thus realistic quantification of metastases could not be 
assured. 
 
5.1.8 Western Blot 
Western blot is a widely established and used method for protein detection and 
quantification in research. Although numerous errors in the lab could arise in this multi-
step process, the results are highly valuable and appreciated in many areas of science. 
Recent advances in technology provide equipment that leads to faster and easier ways 
of performing western blotting as well as improving results.  
In this study, we initially tried lysating the tumor tissue with the newly developed 
Bioruptur machine (Biorupture®Pico, Diagenode, Seraing, Belgium) because it lyses 
both tissues and cells. Unfortunately, we had to use 12-15 cycles (significantly more 
than the manual suggested) before complete tissue lysis and our results yielded very 
low signals. Our hypothesis is that the epitope for E-cadherin and N-cadherin were 
destroyed by this method. We also predicted that this could occur if we used a sonicator, 
so only the centrifuge was used in the end for tissue lysis.  
We observed a markedly different loading concentration in β-actin, and even though 
adjustments for this difference through densitometry was performed, the optimal way 





The present study showed reduced primary tumor growth and reduced metastatic effect 
of HBO treatment in triple negative human (MDA-231) and murine (4T1-L) breast tumor 
models in in vivo. Further, the EMT marker, N-cadherin was significantly downregulated 
by HBO treatment in the MDA-231 xenograft. There seemed to be an insignificant effect 
on tumor growth and metastasis in the murine (4T1) allograft. 
 
5.2.1 Tumor growth estimation 
Because hypoxia is a common feature in tumors and generally accepted as a promoter 
of aggressive tumor growth and metastatic potential, we wanted to target the hypoxic 
tumor microenvironment. This was conducted by investigating the effect of enhanced 
tissue oxygenation by HBO treatment in murine and human breast tumor models. 
4T1 and 4T1-L 
The present study showed no significant difference in 4T1 primary tumor growth 
between treated and control, indicating that 2.5 bar HBO exposure did not effectively 
reduce tumor growth. This is not in agreement with previous studies showing reduced 
tumor growth found in 4T1 and chemically induced breast tumor models in response to 
HBO treatment (57, 86, 87, 95). In fact, DMBA-induced tumor growth seemed to be dose 
dependent and 2.0 bar HBO exposure lead to a smaller tumor size than initially at day 1 
(57). It is worth mentioning however, that DMBA-induced tumor models are more 
heterogeneous and represent endocrine receptor-positive breast cancer which is less 
aggressive than the TNBC cell type 4T1. 
Nevertheless, because the 4T1 tumor growth response to HBO was unexpected due to 




(4T1-L) that in addition could visualize the effects on tumor size and metastasis in vivo. 
There was a significant reduction in tumor growth in response to HBO compared to 
control in this latter model. This was also in accordance with the in vivo images that 
displayed smaller tumor size in HBO-treated mice. The tumor did not however, shrink as 
the DMBA-induced tumors did. Because 4T1 cells were obtained from a different 
provider, there is a possibility that 4T1-L cells behaved differently and were not as 
aggressive as in accordance with previous research.  
The unexpected 4T1 tumor growth response could however, be due to numerous 
reasons. Perhaps the most reasonable hypothesis is that the 4T1 tumor cells have 
undergone several mutations and become significantly more aggressive than the once 
used earlier by our laboratory. The degree of sub-culturing a cell line (passage number) 
affects the cell´s characteristics such as responses to stimuli, morphology, protein 
expression and growth rate (96). Although the underlying mechanisms are poorly 
understood, compelling data of passage-dependent effects on mammalian cell lines has 
accumulated through these past two decades (96). A study comparing low and high 
passage number in human prostate cancer cells reported that high passage number 
correlates to changes in PI3K/Akt pathway, which may have implications in various 
stages of prostate cancer (97). Hence, cell lines at high passage numbers may develop 
malignant transformation. It is therefore of interest to ensure low passage number to 
produce reliable and reproducible results. Since we used passage number 8 and 9 for 
our present study which is generally not considered “high”, we don’t believe this would 
have any major effects on the 4T1 cells behavior. However, cells within a cell culture 
compete for nutrients and cells growing faster, can outgrow other cells. This “survival of 
the fittest” concept can give rise to transforming cells that do not resemble the original 
starting material. Contamination from previous improper laboratory work could also 
influence the cell culture environment and contribute to cell differentiation. Thus, it is of 
interest to continuously test and examine the cell line of use and compare it to the 





Since the hyperbaric chamber has been moved to another location compared to 
previously mentioned studies, it was of great interest to ensure that the hyperbaric 
chamber had 100% pure oxygen at the specific flushing and pressurizing protocol we 
used. Thus, the technicians at our department controlled for this and confirmed that our 
HBO exposure profile was accurate.  
Nevertheless, due to the well documented effects of HBO treatment we can still 
conclude that it reduces murine breast tumor growth (previous 4T1 studies and the 
present 4T1-L) and that our results from 4T1 deviate from this conclusion. The reason 
for the lack of HBO treatment response in the 4T1 model is therefore not elucidated at 
the present time. 
MDA-231 
Reduced tumor growth was found in the human MDA-231 breast tumor model after HBO 
treatment compared to controls. All tumors were still significantly larger on the last day 
compared to day 1. Although research is lacking on the HBO treatment effects on 
human breast tumors, our results correspond to previous research in chemically induced 
(DMBA) and murine breast tumor growth (57, 86, 87, 95) Thus, murine and human 
breast tumor models seem to share a common oxygen dependent inhibitory growth 
mechanism. The anti-tumor effects of HBO treatment could be pro-apoptotic, anti-
proliferative and anti-angiogenic as previously found breast tumor models in vivo (57, 
86, 87).   
 
5.2.2 Metastasis 
Since tumor hypoxia is associated with increased metastatic ability as stated in the 
introduction (52), we hypothesized a reduction in the metastatic potential of tumor cells 
after HBO treatment. Histological examination of H&E stained sections in the different 





Macroscopic surface metastases were observed in the lungs of control and HBO-treated 
mice with MDA-231, 4T1 and 4T1-L primary tumors. The presence of tumor cell 
metastases in the lungs is in accordance with the findings of Tao et al. (76) and Minn et 
al. (98) where 4T1 and MDA-231 lung metastases were visualized by biophotonic 
imaging. The metastatic potential in the 4T1 tumor model was significantly higher than in 
MDA-231 model, as to be expected since they are more aggressive. Duration of 
experiments with 4T1 cells do not normally exceed 30 days due to severe growth of 
primary tumors in mice. Since 4T1 tumor growth is also more aggressive, one can 
speculate if there is a correlation between tumor growth aggressiveness and metastatic 
potential. Interestingly, the possible causality between tumor size and metastatic risk to 
lungs in breast cancer have been investigated through the previously defined “lung 
metastasis gene-expression signature” (LMS) study (99). The data indicated that a 
confirmed LMS in the metastatic tumor confer primary tumor cell growth advantage and 
hence, tumor growth can be a marker for metastasis. 
HBO and 4T1 and 4T1-L lung metastasis 
The results indicate that HBO treatment did not reduce the metastatic potential of the 
4T1 tumor model compared to control. A similar study conducted by our research group 
also discovered no impact of HBO treatment on the metastatic capability of the 4T1 
tumor model over time (100). However, as this was performed with a different HBO 
protocol and on nod/scid mice, the results may not be totally comparable. Another study 
observed a significant reduction in large 4T1 tumor colonies in the lungs after 
intravenous injection (101). One could hypothesize that if 4T1 tumor growth was 
significantly reduced by HBO treatment as in accordance with previous studies (57, 73, 
86), the metastatic potential would also be reduced (99). This could also be applied to 






HBO and MDA-231 lung metastasis 
Interestingly, HBO treatment showed significant effects on reducing the metastatic 
potential of MDA-231 tumor cells to lungs. Existing research concerning HBO treatment 
effects on human breast cancer metastasis models is lacking. Therefore, since the 
MDA-231 cell line is of human origin and represent the most negative prognostic breast 
cancer type (triple negative), these findings can be of great clinical importance and 
needs therefore to be studied further.  
Metastatic effect of HBO 
Given that HBO reduces the hypoxic state of tumors, the reduced metastatic potential of 
tumor cells must be attributed to the effects of enhanced tumor oxygenation. In addition, 
since low tumor pO2  in patients is associated with increased metastatic potential stated 
in the introduction (58, 59), certain steps in the metastatic cascade must be hindered by 
hyperoxia. Since HBO treatment reduces tumor growth, one could also hypothesize 
reduced metastatic potential. In particular, the reduced tumor cell proliferation, vascular 
density and increased apoptosis render tumors less aggressive, indicating reduced 
malignancy. Although research concerning HBO effects on the metastatic cascade is 
lacking, several studies could not find metastasis induction after HBO treatment in mice 
with different cancer types (87, 102, 103). Furthermore, Haroon et al. (101) observed a 
significant reduction in large 4T1 tumor colonies in the lungs after intravenous injection 
indicating that HBO treatment is not prometastatic, but restricts tumor cell growth. The 
significant reduction in the metastatic ability of human and murine breast tumors after 
HBO treatment indicates that oxygen might be a contributing factor in metastasis. 
Furthermore, since HBO treatment has previously shown to induce MET (57) which is 
believed to counteract the malignant effect of EMT in metastasis progression, this 






HBO and EMT 
As stated, hypoxia has shown to predispose for tumor metastases through induction of 
EMT (54, 55). Furthermore, it is well established that highly aggressive epithelial tumors 
display a change in cadherin expression by an upregulation of N-cadherin and 
downregulation of E-cadherin (104). Therefore, the major EMT markers, E cadherin and 
N-cadherin expression in primary tumor lysates was investigated. Our results showed a 
significant reduction in N-cadherin expression in MDA-231 tumor lysates after treatment 
compared to controls. E-cadherin expression seemed to be unaffected in the two 
groups. These results indicate that EMT was affected to some extent by HBO which 
could be contributing to the reduced metastatic potential of MDA-231 tumor cells. To 
elucidate whether the effects incused MET, several other expression analyses are 
needed. However, these results are in accordance with the previous study where 
induction of MET was mainly characterized by a decrease in N-cadherin and increase in 
E-cadherin after HBOT (57). As DMBA-tumor models are more heterogenous and could 
be considered less aggressive than the highly invasive human MDA-231 model, this is 
particularly promising.  
However, the seemingly unaffected expression of E-cadherin remains to be elucidated. 
Normally, a loss of E-cadherin expression is typically the most representative 
occurrence in EMT because it is a cell-cell adhesion facilitator (105). In addition, 
decreased expression of E-cadherin has been seen invasive breast cancers and a 
recent study reported that EMT and its associated downregulation of E-cadherin is 
required for the development of metastasis (106). Due to the aggressiveness of the 
MDA-231 cells compared to the DMBA-induced model, the effects of HBO treatment 
could have had less impact E-cadherin expression. 
On the other hand, highly invasive breast tumors have shown to contain upregulated N-
cadherin expression (107). A knockdown of N-cadherin lead to cell increased apoptosis, 
decreased invasiveness in vitro and inhibition of metastatic tumor formation in vivo was 




transgenic mice containing a mammary tumor promoter lead to increased lung breast 
tumor cell motility and metastases compared to control (109). Another study found that 
breast tumor cells “forced” to express N-cadherin did not show a downregulation of E-
cadherin but still promoted motility and invasion (110), indicating that N- is dominant 
over E-cadherin and that its expression alone contributes to malignant progression and 
therefore not a consequence of it. 
Hazan et al. (107) reported that N-cadherin promoted breast cancer metastasis through 
interactions between the breast tumor cells and stromal cells. HBO treatment reduces 
the hypoxic state of tumors and thus the tumor stroma. One hypothesis could be that the 
effects of enhanced oxygenation changed the interaction between N-cadherin and 
stromal cells and lead to reduced expression of N-cadherin, and that E-cadherin 
expression was more difficult to target by HBO. However, much needs to be elucidated 
in the mechanisms behind these changes in the tumor microenvironment.  
In summary, as N-cadherin plays a direct role in promoting tumor cell motility and 










The overall aim was to target the hypoxic environment. 
We have adressed and answered the following specific sub-aims: 
1. Investigate the effect of hyperbaric oxygen treatment on the malignant 
progression of human (MDA-MB-231) and murine (4T1 and 4T1L) breast tumors in 
vivo. 
• Repeated HBO treatment significantly reduced tumor progression in the human 
(MDA-231) and murine (4T1-L) breast cancer model without affecting the murine 
4T1 model. 
• The metastatic ability of human (MDA-231) and murine (4T1-L but not 4T1) tumor 
cells to lungs were also significantly reduced after HBO treatment. 
2. Visualize tumor size and potential metastases in vivo through biophotonic 
imaging 
• In vivo imaging of balb/c mice with primary murine 4T1-L tumors was performed 
without detecting any metastases to distant sites. Reduced primary tumor size 
was observed in HBO-treated mice. 
3. Elucidate if hyperbaric oxygen treatment would influence major epithelial to 
mesenchymal transition markers and thus, the metastatic potential. 
• HBO treatment influenced EMT through downregulation of N-cadherin expression 
in human (MDA-231) primary tumors. The reduced metastatic potential could 





5.4 Future perspectives 
The present study was part of a larger collaboration project and in order to minimize the 
number of animals, frozen tumors, tumor lysates and organs were stored for later 
additional analyses. 
Future studies should further investigate tumor progression and reduced metastatic 
potential effect of HBO treatment on different human breast cancer models. In particular, 
since metastasis is responsible for most cancer-related deaths, any therapy that could 
reduce the metastatic potential is important.  
Factors involved in the development of metastasis should be investigated to better 
understand the mechanisms behind the metastatic cascade. This would enable 
successful cancer therapies. As EMT is considered a crucial initial step in metastasis 
development, additional effectors other than E- and N-cadherin is likely to yield new 
insights into metastasis. In particular, expression analysis of contributing factors to EMT 
should be elucidated in order to establish if MET is induced by HBO. The transforming 
growth factor beta (TGF-β) signaling pathway has been implicated in the several aspects 
of the metastatic process and is thought to contribute to EMT by inducing E-
cadherin.(111). It would be interesting to look at expression of  TGF-β in different cell 
lines to possibly verify that E-cadherin is in fact, downregulated. More importantly, if E-
cadherin expression is in fact unaffected by HBO treatment in human breast tumor cells, 
we could implement TGF-β-knock out mice in HBO treatment. Other inducers of EMT; 
TWIST and SNAIL that have shown to correlate with elevated characteristics of breast 
cancer stem cells (BCSC) contributing to cancer progression (112, 113). 
Moreover, the receptor tyrosine kinase Axl is induced by EMT and show enhanced 
expression in metastatic breast tumors. Enhanced expression is correlated with reduced 
overall survival in breast cancer patients. More interestingly, a complete prevention of 
metastasis in highly invasive breast tumors was seen when Axl was knocked out (114). 




as well as targeted treatment of Axl-expressing tumors. 
Breast cancer research have identified several useful metastatic markers associated 
with a poor prognosis  An extensive assessment identified several genes that mediate 
breast cancer metastasis to the lungs through in vivo selection and transcriptomic 
analyses (98). Interesting genes encoding for the epidermal growth factor family 
member epiregulin (EREG), the MMP collagenase (MMP1), the cell adhesion molecule 
(SPARC) and the cell adhesion receptor (VCAM1). As they have established a lung 
metastatic signature in an MDA-231 model, identification of those genes in the primary 
and metastatic tumor after HBO treatment would be interesting since tumors expressing 
the signature predict poorer overall survival (98).  
Furthermore, the tumor microenvironment has gained special interest due to its 
contribution of tumor progression and metastasis. As stated in the introduction, the 
“seed and soil” theory explains the variance between metastatic sites in different cancer 
types. Investigation into the pre-metastatic niche prior to the development of metastasis 
could yield new insights into the mechanisms behind the development of this favorable 
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Appendix A. Buffer recipes for Western Blot protocol 
Lysis buffer: 
• 50 mM Tris-HCl (pH 7.4) 
• 150 mM NaCl 
• 1% Trition X one  
• 1 EDTA-free cOmplete Mini tablet 
• 1 PhosStop phophatase inhibitor 
TBS (1x): 
• 100 ml 10x TBS 
• 1000 ml ddH2O 
TBS-T (1x): 
• 100 ml 10x TBS 
• 1000 ml ddH2O 
• 1 ml Tween®20 
I-block buffer: 
• 100 ml 10x TBS 
• 1000 ml ddH2O 
• 2 g I-Block 
• Warm until 70°C and cool down to 20°C 
• 1 ml Tween®20 
• 1 ml 20% NaN3 (0,2 g in 1 ml) 







Tris-HCL (Trizma® hydrochloride): Sigma Aldrich, Steinheim, Germany 
NaCl (Sodium chloride): Mona Grønningen, University of Bergen 
1% Trition X: X000, Sigma-Aldrich, Steinheim, Germany 
EDTA-free cOmplete Mini tablet: Roche Diagnostics, Manheim, Germany 
PhosStop phosphatase inhibitor: Roche Diagnostics, Manheim, Germany 
TBS (10x): G-Biosciences, St.Louis, USA 
I-Block: Tropix®, Applied Biosystems, Thermo Scientific, Bedford, USA 
Tween®20: Sigma-Aldrich, Steinheim, Germany 
NaN3 (sodium azide): Sigma Aldrich, Steinheim, Germany 
MgCl2*6H2O (magnesium chloride hexahydrate): Sigma Aldrich, Steinheim, 
Germany 
 
